Gene-editing biotech CRISPR Therapeutics $CRSP could change medicine for heart disease, blood disorders, cancer, and diabetes. They already have FDA-approved Casgevy for sickle cell disease, and their new CTX310 data shows a 50% drop in cholesterol and triglycerides. CRISPR also partners with biotech giant Vertex, giving them money, resources, and real support. It’s still a clinical-stage biotech, so the stock is volatile, but the potential is there if things work out. Could this be the next big